---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-021552"
form_type: "8-K"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:44:14.309950+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protagenic Therapeutics granted Japan patent for modified stilbenoid epilepsy drug candidates

## Summary
- Japanese Patent Office granted Patent JP 7714571B on July 18, 2025, covering modified stilbenoid compounds.
- Patent runs until March 31, 2041, providing exclusivity for treating epilepsy and seizures.
- Builds on previously granted UK patent GB2609814 for same program.
- Japanese pharma market worth >$85B; global epilepsy drug market expected to reach $18.7B by 2034.
- Company expects to expand patent protection to other territories.

## SEC filing metadata
- accession: 0001641172-25-021552
- form_type: 8-K
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225021552/0001641172-25-021552-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225021552/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-021552
- JSON: https://secwatch.observer/filing/0001641172-25-021552.json
- Plain text: https://secwatch.observer/filing/0001641172-25-021552.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.